Abstract 47P
Background
In CRC molecular studies have shown that there is a great inter-tumour heterogeneity (ITH) within each UICC TNM stage and therefore a range of other transcriptional and protein biomarkers need to be investigated independently of the UICC TNM staging. In CRC, one of these adverse prognostic factors is tumour budding, Typically, tumour budding is assessed using H&E-stained specimens but scoring methods and grading schemes vary widely. A retrospective study was carried out to study the differential expression of discriminative markers in matched invasion fronts and tumour buds of 44 patients with stage 3/4 CRC disease.
Methods
A retrospective study was done on 44 Formalin Fixed paraffin embedded tissue sections with at least stage 3/4 CRC disease. These cases were used to study the expression differences between the central portion of the tumour, the invasion front and the tumour buds using the Luminex bead-based assay. The different tumoral compartments were assessed by a pathologist on a H&E stained slide and a 0.5mm core was obtained from each respective area on the specimen block. The core was lysed for 18 – 22 hrs at 58°C. After overnight incubation, hybridization-based assay was performed to study the expression of 50 different genes. Data analysis was carried out to see if there is any statistically significant difference between the central portion of the tumour, the invasion front and tumour buds.
Results
A statistically significant differences was noted in the expression of TRIB1 and CCND3 when comparing the central portion of the tumour to the tumour buds. The expression of TRIB1 and CCND3was higher in the buds than that of the central tumour. A statistically significant difference was seen in the expression of CDX2 when comparing the invasion front to the tumour bud. CDX2 was higher in the invasion front than in the tumour buds. A statistically significant difference was also seen in the expression of MCL1 which was higher in the invasion fronts when compared to the central tumour part.
Conclusions
With the use of a bead based multiplex assay we were able to carry out differential expression of a number of genes related to invasiveness, metastasis and treatment resistance in matched central tumour, invasion fronts and tumour buds in CRC patients.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Emanuele Cancer Research Foundation Malta.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
125P - Combination of navitoclax with alpelisib and trametinib to synergistically impair cell viability in high-grade ovarian cancer
Presenter: Lisa Wozelka-Oltjan
Session: Cocktail & Poster Display session
Resources:
Abstract
126P - Effect of sequential antitumoral treatment with immune checkpoint blockade and tyrosine kinase inhibitors in hepatocellular carcinoma
Presenter: Vincenza Ciaramella
Session: Cocktail & Poster Display session
Resources:
Abstract
127P - Novel bone-targeting of activatable sirolimus for targeted therapy of bone-resident cancers
Presenter: Alistare Sadra
Session: Cocktail & Poster Display session
Resources:
Abstract
128P - Network medicine approach identifies small molecule drugs as immune checkpoint inhibitors repurposable for rectal cancer
Presenter: Faheem Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
129P - Repurposing existing therapies for adrenal cancer: Unlocking new possibilities
Presenter: Anupama Samantasinghar
Session: Cocktail & Poster Display session
Resources:
Abstract
130P - Restoration of the mutant p53 protein upon treatment with small molecule modulators
Presenter: Elvina Gilyazova
Session: Cocktail & Poster Display session
Resources:
Abstract
131P - Trop 2 and its overexpression in metastatic colorectal cancer patients (mCRCp): Biological, clinical and therapeutic implications
Presenter: Andrea Mancuso Petricca
Session: Cocktail & Poster Display session
Resources:
Abstract
132P - Novel small molecule modulators for activation of mutant tumor suppressor p53
Presenter: Damir Davletshin
Session: Cocktail & Poster Display session
Resources:
Abstract
133P - Cytotoxic efficacy of artificial vesicles obtained from CAR-T cells by ultrasonication
Presenter: Ekaterina Zmievskaya
Session: Cocktail & Poster Display session
Resources:
Abstract
134P - Doxorubicin and olaparib (OLA) synergism in high-grade serous ovarian (HGOC) and triple-negative breast cancer (TNBC) cell lines with olaparib-resistance
Presenter: Jose Alejandro Perez Fidalgo
Session: Cocktail & Poster Display session
Resources:
Abstract